Generated by AI
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies using its ExacTcell™ platform to harness CD8+ cytotoxic T lymphocytes for treating infectious diseases, cancers, and neurological disorders. The company targets antigens present only on diseased cells to spare healthy tissue, enhancing safety through naturally occurring T cell receptors, with applications spanning oncology, neurology, and virology. Key product candidates include TVGN 489, which has completed Phase 1 trials for high-risk COVID-19 patients and is in Phase 1 for acute SARS-CoV-2 in B-cell suppressed individuals and Long COVID; TVGN 920 and TVGN 960 in preclinical stages for cervical and oropharyngeal cancers; TVGN 601 for multiple sclerosis; TVGN 930 for Epstein-Barr virus-associated lymphomas; and TVGN 116 for hepatitis B. Tevogen Bio Holdings Inc. also advances Tevogen.AI, applying proprietary predictive technologies like PredicTcell™ to accelerate drug development through immunologically active peptide identification. Founded in 2020 and headquartered in Warren, New Jersey, the company focuses on making therapies commercially viable and accessible to broad patient populations in the biotechnology sector.
Website15 Independence Boulevard
Warren, NJ, 07059
United States
The latest articles about TVGN.
Up to $28.6 million in borrowing capacity through May 2029 WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), a healthcare company focused on combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, has extended the end of the borrowing period under its existing loan agreement with The Patel Family, LLP from May 2027 to May 2029. The facility permits borrow
Tipranks Press Release.
Tevogen Bio Holdings (TVGN) said Wednesday it received written notice from Nasdaq on Sept. 29 confir
Summary of May 14's posts. Generated by AI.
Summary of Dec 9's posts. Generated by AI.
Summary of Aug 5's posts. Generated by AI.
No summary yet.
Summary of Mar 6's posts. Generated by AI.
Investors talking about TVGN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.